Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL VI: IDegLira Titration in Type 2 Diabetes
NCT02298192Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2014
- Primary completion
- Dec 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change From Baseline in HbA1c at 32 weeks. Started Nov 2014; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02298192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02298192.